Dividend and Financial Performance - The Company has not declared an interim dividend for the six months ended June 30, 2024, consistent with the previous year[5]. - For HY2024, the Group recorded total revenue of HK$42,403,000, an increase from HK$29,911,000 in HY2023[26]. - The Group reported a loss of HK$917,000 for HY2024, compared to a profit of HK$1,938,000 in HY2023[26]. - As of June 30, 2024, the basic and diluted loss per share was HK$0.2 cents, compared to earnings of HK$0.01 cents per share on June 30, 2023[27]. - The Group's consolidated net assets were HK$432,113,000 as of June 30, 2024, slightly up from HK$430,465,000 on December 31, 2023[27]. - The Company reported a total comprehensive loss for the period of HK$17,937,000 for the six months ended June 30, 2024, compared to a total comprehensive loss of HK$78,683,000 for the same period in 2023[180]. Business Operations and Strategy - The Company is focusing on expanding its longevity science business while managing existing operations in money lending, financial advisory, securities, and property investment[6]. - The money lending and financial advisory business has been restructured to comply with new PRC guidelines, transitioning to a non-P2P model[8]. - The focus on longevity science is part of a broader strategy to diversify and strengthen the Company's market position[6]. - The Company continues to adapt to regulatory changes in the PRC financial landscape, ensuring its business model aligns with current guidelines[8]. - The Group is focusing on enhancing its longevity science business through membership and distribution channels, indicating a commitment to future growth[26]. Regulatory Compliance and Restructuring - The PRC subsidiary, Tian Xing, has normalized its operations and restored its status with regulatory departments, including the Beijing Commerce Department and the Beijing Taxation Bureau[8]. - The Company has successfully regained possession of all necessary company chops and seals for its PRC subsidiary during 2023[8]. - The restructuring of the money lending business follows the cessation of the Caijia Peer-to-Peer Internet Credit Youtoubao loan platform due to regulatory changes[7]. - The Company has hired new staff and disassociated from all former managerial personnel in Tian Xing to ensure compliance and operational integrity[8]. - The Company is committed to maintaining compliance with evolving regulations in the financial sector to safeguard its operations and reputation[8]. Revenue and Segment Performance - The longevity science business generated revenue of approximately HK$25,180,000 for HY2024, compared to HK$11,868,000 in HY2023[28]. - Revenue from diagnostic consultation and medical testing was approximately HK$21,700,000, while sales of longevity biological products contributed approximately HK$3,480,000[28]. - The money lending and financial advisory business maintained static revenue of HK$17,223,000 with a segment profit of HK$16,233,000 for HY2024[26]. - The segment loss for the longevity science business was approximately HK$4,342,000 for HY2024, an improvement from HK$13,283,000 in HY2023[28]. - Loan interest income for the period was HK$17,223,000, slightly down from HK$18,043,000 in 2023, reflecting a decrease of approximately 4.5%[192]. Cash Flow and Financial Position - Cash and bank balances were approximately HK$78,705,000 as of June 30, 2024, down from HK$81,075,000 as of December 31, 2023[86]. - The Group recorded net current assets of approximately HK$255,761,000 as of June 30, 2024, compared to HK$250,127,000 as of December 31, 2023[86]. - Net cash used in operating activities was HK$16,000 for the six months ended June 30, 2024, a significant improvement from HK$15,849,000 in the prior year[183]. - Cash flows from investing activities generated a net cash inflow of HK$2,089,000 for the six months ended June 30, 2024, compared to HK$12,000 in the same period of 2023[183]. - The net increase in cash and cash equivalents for the period was HK$20,921,000, compared to a decrease of HK$6,026,000 in the same period last year[184]. Share Capital and Options - The total number of issued ordinary shares increased to 546,529,549 as of June 30, 2024, from 455,441,291 as of December 31, 2023[90]. - The Company issued an additional 91,088,258 shares during HY2024[90]. - As of June 30, 2024, the number of share options available for grant under the 2022 Share Option Scheme was 38,701,026 shares[114]. - No share options were granted under the 2022 Share Option Scheme for HY2024, resulting in no outstanding share options as of June 30, 2024[120][123]. - The maximum entitlement for each participant under the 2022 Share Option Scheme is limited to 1% of the total number of shares of the Company in issue at the date of grant within any 12-month period[121][124]. Environmental and Corporate Governance - The company is committed to environmental sustainability and will issue its environmental, social, and governance report for the year ending December 31, 2024, in the next annual report[170]. - The Company has complied with the Corporate Governance Code during HY2024[158]. - All existing Directors confirmed compliance with the Model Code for Security Transactions during HY2024[161].
中基长寿科学(00767) - 2024 - 中期财报